iNtRON Biotechnology Inc (048530) — Capital Reinvestment Ratio

Latest as of March 2025: 0.17x

iNtRON Biotechnology Inc (048530) has a Capital Reinvestment Ratio of 0.17x as of March 2025, meaning it reinvests 0% of its operating cash flow (₩1.94 Billion) in capital expenditures (₩321.62 Million). Check iNtRON Biotechnology Inc tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.17x
Capex / Operating Cash Flow

Operating Cash Flow

₩1.94 Billion
KRW

Capital Expenditures

₩321.62 Million
KRW

Data as of

Mar 2025
Most recent filing

iNtRON Biotechnology Inc Capital Reinvestment Ratio (2015–2023)

This chart tracks iNtRON Biotechnology Inc's Capital Reinvestment Ratio across 6 annual periods. For the full cash flow conversion analysis, see iNtRON Biotechnology Inc (048530) cash conversion ratio.

Annual Capital Reinvestment Ratio for iNtRON Biotechnology Inc (2015–2023)

Year-by-year Capital Reinvestment Ratio for iNtRON Biotechnology Inc from 2015 to 2023. See iNtRON Biotechnology Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2023 3.06x ₩3.12 Billion ₩9.55 Billion ▲ +721.6%
2022 0.37x ₩5.98 Billion ₩2.23 Billion ▲ +101.6%
2021 0.18x ₩16.47 Billion ₩3.05 Billion ▼ -72.8%
2020 0.68x ₩7.13 Billion ₩4.85 Billion ▲ +419.1%
2018 0.13x ₩4.20 Billion ₩550.58 Million ▼ -96.5%
2015 3.71x ₩1.70 Billion ₩6.30 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow